Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

JNJ 113.33 +0.64 (0.57%)
price chart
Johnson & Johnson Prostate Cancer Drug Impresses
A new study shows that Johnson & Johnson's prostate cancer pill Zytiga dramatically slows the progression of the disease in men who are not yet sick enough to start chemotherapy.
Johnson & Johnson Latest Company To Break Away From ALEC
Johnson & Johnson is the latest company to break away from the American Legislative Exchange Council (ALEC). On June 12, Johnson & Johnson announced it would stop funding the group that has pushed states to pass voter ID and stand-your-ground ...
Johnson & Johnson Should Split Up Says Goldman
By Peter Loftus. Johnson & Johnson should split into three companies, which could value health-care conglomerate at $76 a share, up more than 20% from current price of $62, Goldman Sachs says.
Johnson & Johnson Announces Completion of Synthes Acquisition
NEW BRUNSWICK, N.J., June 14, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Synthes, Inc. for a total purchase price of $19.7 billion in cash and stock.
Johnson & Johnson's $19.7B Synthes Deal: A Surprise Earnings Boost  Forbes
Johnson & Johnson's Synthes Deal Revives Foreign Tax Debate  TheStreet.com
BREAKING: Johnson & Johnson Drops ALEC
Pharmaceutical giant Johnson and Johnson announced today that they are dropping their membership from the American Legislative Exchange Council (ALEC).
Johnson & Johnson to stop selling surgical mesh
Johnson & Johnson is stopping sales of surgical mesh products that aimed to relieve the intense pelvic pain of thousands of women but resulted in numerous reports of injury and several deaths.
Johnson & Johnson Unit to Halt Urinary Implants  New York Times
Class Action Launched Concerning Johnson & Johnson Discontinuance of ...  Canada NewsWire (press release)
Johnson & Johnson diabetes drug tops older therapies in studies
An experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than Merck & Co's Januvia and an older common treatment, glimepiride, according to data from a pair of late stage clinical trials.
Does Johnson & Johnson Need a Lot More than Just a Band-Aid?
But what people don't realize about this brand is that Johnson & Johnson is primarily a pharmaceutical and medical device company.
Cramer: Johnson & Johnson Could Unlock Value by Splitting Up
Take Johnson & Johnson, for example. The New Brunswick, N.J.-based company makes everything from Band-Aids and Tylenol to knee implants and prescription drugs, all of which are fairly resistant to a global slowdown, Cramer said.
Johnson & Johnson Receives US Regulatory Clearance for Synthes Acquisition ...
NEW BRUNSWICK, N.J., June 12, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received U.S.
FTC approves $21.3 billion J&J-Synthes deal, pending DePuy sale to Biomet  Philadelphia Inquirer (blog)